Pierre Fabre partners with XtalPi for AI-driven robotics in drug discovery

On November 9, 2026, Laboratoires Pierre Fabre and XtalPi announced an agreement to discover novel small-molecule clinical candidates using XtalPi's integrated AI capabilities and robotics platform. The collaboration focuses on oncology, dermatology, and rare diseases, where XtalPi handles de novo molecular design while Pierre Fabre manages compound selection and subsequent development. This partnership aims to accelerate the identification of high-quality clinical candidates for historically difficult drug targets through a combined approach of AI-enabled design and disease biology expertise.